688098 Shanghai Shen Lian Biomedical Corporation
- 5.30
- -0.06-1.12%
Shanghai Shen Lian Biomedical Corporation News
Shenlian Biotech (688098.SH): Net loss of 2.09 million yuan in the first quarter
Gelonghui, April 26 | Shenlian Biotech (688098.SH) released its first quarter report. Operating revenue was 880.58 million yuan, up 7.58% year on year, with a net loss of 2.209 million yuan, after deducting non-net loss of 2.889 million yuan, and basic earnings per share of -0.01 yuan.
Weak Financial Prospects Seem To Be Dragging Down Shanghai Shen Lian Biomedical Corporation (SHSE:688098) Stock
With its stock down 37% over the past three months, it is easy to disregard Shanghai Shen Lian Biomedical (SHSE:688098). To decide if this trend could continue, we decided to look at its weak fundam
Shenlian Biotech (688098.SH): 2023 net profit of 31,518,700 yuan decreased by 48.42% year-on-year
Gelonghui, Feb. 28, 丨 Shenlian Biotech (688098.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 301.4871 million yuan, down 8.25% from the previous year; net profit attributable to owners of the parent company was 31.518,700 yuan, down 48.42% from the previous year.
Pinning Down Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) P/S Is Difficult Right Now
When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3x, you may consider Shanghai Shen Lian Biomedical Corporation (SHSE:688098) as a
[BT Financial Report Instantaneous Analysis] Shenlian Biotech's 2023 Quarterly Report: Performance and Market-based Sales Process in the Face of Challenges
Shenlian Biomedical (Shanghai) Co., Ltd. (stock code: 688098) is a high-tech enterprise focusing on R&D, production and sales of veterinary biological products. The company's main business is veterinary preventive biological products and veterinary diagnostic products, and has two major veterinary drug GMP production bases in Shanghai and Lanzhou. The products already marketed by Shenlian Biotech include pig foot-and-mouth disease vaccine, cattle and sheep foot-and-mouth disease vaccine, swine ring vaccine, foot-and-mouth disease and African swine fever diagnostic reagents. Among them, pig foot-and-mouth disease type O and type A bivalent inactivated vaccines are important products of the company. In terms of assets and liabilities, Shenlian Biotech's 2023 three-quarter report shows that the public
Shanghai Hongchao, a shareholder of Shenlian Biotech (688098.SH), and his co-actors reduced their holdings of the company by a total of 2.35%
Shenlian Biotech (688098.SH) announced that Shanghai Hongchao Industrial Investment Co., Ltd. (“Shanghai Hongchao”), a shareholder of the company...
Shenlian Biotech (688098.SH) obtained the “Veterinary Drug GMP Certificate” and the “Veterinary Drug Production License”
Shenlian Biotech (688098.SH) issued an announcement. The company's Lanzhou branch recently passed the veterinary drug GMP inspection and...
Shenlian Biotech (688098.SH) reported the first three quarter results, net profit of 37.1243 million yuan, a year-on-year decrease of 48.70%
Shenlian Biotech (688098.SH) released its report for the first three quarters of 2023, with revenue of 239 million yuan, the same...
Shen Lian Biomedical Forms Tie-up to Develop African Swine Fever Vaccine
Shanghai Shen Lian Biomedical (SHA:688098) partnered with the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences to research and develop a vaccine against African s
Shen Lian Biotech (688098.SH) released first-half results, with net profit of 9.932 million yuan, a year-on-year decrease of 57.35%
Shen Lian Biotech (688098.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Shen Lian Biomedical Passes Regulatory Inspection
Shanghai Shen Lian Biomedical (SHA:688098) passed the good clinical practice inspection of China's Ministry of Agriculture and Rural Affairs. The regulator inspected the veterinary product manufacture
Shanghai Hongchao, a shareholder of Shenlian Biotech (688098.SH), and its co-actors reduced their holdings of the company by 1.5% by a total of 1.5%
According to the Zhitong Finance App, Shen Lian Biology (688098.SH) announced that on August 2, 2023, the company received a “Notice on the Progress of Implementation of the Share Holding Reduction Plan” from shareholder Shanghai Hongchao and its co-actor Shanghai Fenghong. From May 24 to August 2, 2023, Shanghai Hongchao and its co-actor Shanghai Fenghong reduced their holdings by a total of 6.154,900 shares, accounting for 1.5% of the company's total share capital. The amount of holdings reduced in this holdings reduction plan has been reduced by more than half, and the implementation of the holdings reduction plan has not yet been completed.
Shanghai Fenghong, a shareholder of Shenlian Biotech (688098.SH), and his co-actors reduced their holdings by 1.04% to less than 5% of total shares and apologized for violating credit disclosure regulations by reducing their holdings
According to the Zhitong Finance App, Shen Lian Biotech (688098.SH) announced that on July 6, 2023, the company received “Instructions on Changes in Shareholders' Equities and Apologies” and “Simplified Equity Change Report” issued by the shareholder Shanghai Hongchao Industrial Investment Co., Ltd. (hereinafter referred to as “Shanghai Hongchao”) and its co-actor Shanghai Fenghong Technology Development Partnership (Limited Partnership) (hereinafter referred to as “Shanghai Fenghong”), as of July 5, 2023, Shanghai Hongchao and its co-actor, Shanghai Fenghong, reduced centralized bidding and bulk trading methods 4.255,800 shares Shares (change ratio is 1.0
Shen Lian Biology (688098.SH): Shanghai Hongchao and its co-actor Shanghai Fenghong's shareholding ratio decreased from 5.19% to 4.15%
On July 6, 2023, GLONGHUI | Shenlian Biology (688098.SH) announced that on July 6, 2023, the company received “Instructions on Shareholders' Equity Changes and Apologies” and “Simplified Equity Change Report” from shareholder Shanghai Hongchao and his co-actor Shanghai Fenghong. As of July 5, 2023, due to centralized bidding and bulk trading methods, the shareholding ratio of Shanghai Hongchao and its co-actor Shanghai Fenghong had decreased from 5.19% to 4.15%, and the equity change ratio was over 1%. From May 25, 2023 to July 5, 2023, Shanghai Hongchao and his co-actor Shanghai
Shen Lian Biomedical's Bovine Vaccine Passes Regulatory Evaluation
Shanghai Shen Lian Biomedical's (SHA:688098) vaccine for bovine nodular skin disease passed the emergency evaluation of the Ministry of Agriculture and Rural Affairs, the company said in a Friday disc
Shanghai Shen Lian Biomedical Ties Up With Caremed Biomedical to Set Up Joint Venture
07:32 AM EDT, 04/19/2023 (MT Newswires) -- Shanghai Shen Lian Biomedical (SHA:688098) proposed to establish a joint venture with Suzhou Caremed Biomedical Technology. The Chinese veterinary biological
Express News | Shen Lian Biomedical Gets Marketing Approval for Pig Vaccine in China
Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) 27% Share Price Surge Not Quite Adding Up
Shanghai Shen Lian Biomedical Corporation (SHSE:688098) shares have had a really impressive month, gaining 27% after a shaky period beforehand. But not all shareholders will be feeling jubilant, si
Shanghai Shen Lian Biomedical's (SHSE:688098) Anemic Earnings Might Be Worse Than You Think
Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) stock showed strength after its weak earnings report. While shareholders may be willing to overlook soft profit numbers, we believe that the
Express delivery of evening announcement of listed companies on December 27th
Longma Sanitation: the securities abbreviation will be changed to "Fulongma" Longma Sanitation (603686) on the evening of December 27th, and the company's securities abbreviation will be changed from "Longma Sanitation" to "Fulongma" from January 4, 2022. China Telecom Corporation: Zhu Min resigned as Executive Vice President due to job transfer China Telecom Corporation (601728) announced on the evening of December 27th that Zhu Min has resigned as Executive Director, Executive Vice President, Chief Financial Officer and Secretary of the Board of Directors due to job transfer. Botian environment: CIC innovation plans to reduce its holdings by no more than 1.
Analysis
Price Target
No Data
